| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | +38% | $694,720,745 | +$237,235,847 | 8,928,574 | +52% | FMR LLC | 31 Dec 2025 |
| BAKER BROS. ADVISORS LP | 11% | +14% | $551,236,913 | +$127,711,627 | 8,676,797 | +30% | Baker Bros. Advisors LP | 09 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 8.5% | $436,311,906 | 6,867,809 | BVF PARTNERS L P/IL | 11 Dec 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 7.7% | -17% | $240,614,612 | -$27,985,329 | 5,372,061 | -10% | Wellington Management Group LLP | 30 Jun 2025 |
| VANGUARD GROUP INC | 8% | $173,996,098 | 5,231,392 | The Vanguard Group | 31 Mar 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.1% | $288,530,046 | 5,097,704 | T. Rowe Price Associates, Inc. | 30 Sep 2025 | |||
| BlackRock, Inc. | 5.4% | $165,983,856 | 3,803,227 | BlackRock, Inc. | 30 Jun 2025 |
As of 30 Sep 2025, 207 institutional investors reported holding 80,869,300 shares of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR). This represents 101% of the company’s total 79,719,412 outstanding shares.
The largest institutional shareholders of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 8.3% | 6,651,429 | 0% | 2.7% | $376,470,881 |
| Avoro Capital Advisors LLC | 8% | 6,350,000 | -3.1% | 4.6% | $359,410,000 |
| FMR LLC | 7.4% | 5,879,611 | +8.2% | 0.02% | $332,785,989 |
| BVF INC/IL | 6.9% | 5,502,710 | 0% | 13% | $311,453,386 |
| VANGUARD GROUP INC | 6.8% | 5,421,722 | -3.5% | 0% | $306,869,465 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.5% | 5,195,691 | -3.3% | 0.05% | $294,076,110 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.4% | 5,097,378 | -26% | 0.03% | $288,513,000 |
| Atlas Venture Life Science Advisors, LLC | 6.1% | 4,896,462 | 0% | 37% | $277,139,749 |
| BlackRock, Inc. | 5.5% | 4,365,448 | +5.2% | 0% | $247,084,359 |
| Siren, L.L.C. | 4.3% | 3,428,150 | 0% | 7.6% | $194,033,290 |
| STATE STREET CORP | 2.5% | 2,019,454 | +30% | 0% | $114,301,096 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,276,766 | +7% | 0% | $72,276,364 |
| Capital Research Global Investors | 1.6% | 1,262,182 | 0% | 0.01% | $71,439,501 |
| JENNISON ASSOCIATES LLC | 1.3% | 1,027,739 | +25% | 0.03% | $58,170,027 |
| Driehaus Capital Management LLC | 1.2% | 939,094 | +0.56% | 0.38% | $53,152,720 |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 1.1% | 863,762 | +5.5% | 0.01% | $48,888,930 |
| Holocene Advisors, LP | 1.1% | 840,333 | 0.11% | $47,562,848 | |
| Merck & Co., Inc. | 0.97% | 772,165 | 0% | 19% | $43,704,539 |
| Commodore Capital LP | 0.94% | 750,000 | 0% | 2.1% | $42,450,000 |
| DIMENSIONAL FUND ADVISORS LP | 0.92% | 731,420 | +30% | 0.01% | $41,409,153 |
| GOLDMAN SACHS GROUP INC | 0.89% | 711,444 | +155% | 0.01% | $40,267,730 |
| UBS Group AG | 0.81% | 648,718 | +16% | 0.01% | $36,717,439 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.81% | 644,590 | +14% | 0.6% | $36,483,859 |
| Alyeska Investment Group, L.P. | 0.77% | 615,091 | +1130% | 0.11% | $34,814,151 |
| T. Rowe Price Investment Management, Inc. | 0.77% | 611,221 | +574% | 0.02% | $34,596,000 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 54,323 | $4,227,245 | +$1,177,507 | $77.81 | 10 |
| 2025 Q3 | 80,869,300 | $4,577,065,145 | +$137,544,867 | $56.60 | 207 |
| 2025 Q2 | 78,801,021 | $3,438,754,240 | +$270,821,262 | $43.64 | 208 |
| 2025 Q1 | 72,808,716 | $1,995,263,098 | +$5,348,226 | $27.37 | 171 |
| 2024 Q4 | 71,721,890 | $2,885,022,540 | +$14,409,751 | $40.23 | 177 |
| 2024 Q3 | 69,051,239 | $3,268,392,680 | +$183,360 | $47.33 | 174 |
| 2024 Q2 | 67,390,465 | $2,011,640,213 | +$5,551,590 | $29.85 | 153 |
| 2024 Q1 | 67,207,302 | $2,701,742,064 | +$296,832,171 | $40.20 | 161 |
| 2023 Q4 | 60,455,852 | $1,539,280,108 | +$89,020,891 | $25.46 | 134 |
| 2023 Q3 | 57,350,132 | $797,188,696 | -$18,249,775 | $13.90 | 120 |
| 2023 Q2 | 58,230,116 | $1,338,678,295 | +$29,100,921 | $22.99 | 124 |
| 2023 Q1 | 56,859,649 | $1,683,467,091 | +$23,131,891 | $29.63 | 123 |
| 2022 Q4 | 56,195,243 | $1,402,708,961 | +$98,529,765 | $24.96 | 116 |
| 2022 Q3 | 52,859,306 | $1,150,805,258 | +$29,150,428 | $21.77 | 119 |
| 2022 Q2 | 49,442,050 | $973,574,555 | +$16,502,218 | $19.69 | 99 |
| 2022 Q1 | 45,688,568 | $1,933,296,396 | +$62,437,636 | $42.32 | 124 |
| 2021 Q4 | 43,015,870 | $2,729,867,438 | +$128,644,677 | $63.49 | 123 |
| 2021 Q3 | 34,637,185 | $2,035,073,191 | +$491,859,746 | $58.74 | 115 |
| 2021 Q2 | 26,479,657 | $1,284,263,574 | +$188,105,374 | $48.50 | 109 |
| 2021 Q1 | 22,191,421 | $862,345,865 | +$92,686,286 | $38.86 | 94 |
| 2020 Q4 | 20,299,967 | $1,247,002,136 | +$53,009,741 | $62.00 | 74 |
| 2020 Q3 | 16,828,031 | $542,529,000 | +$542,529,000 | $32.31 | 51 |